State Street’s Verrica Pharmaceuticals VRCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $177K | Hold |
28,916
| – | – | ﹤0.01% | 3863 |
|
|
2026
Q1 | $153K | Buy |
28,916
+5,435
| +23% | +$34.8K | ﹤0.01% | 3952 |
|
|
2025
Q4 | $195K | Buy |
23,481
+2,900
| +14% | +$16.1K | ﹤0.01% | 3906 |
|
|
2025
Q3 | $88.7K | Buy |
20,581
+11,399
| +124% | +$68.7K | ﹤0.01% | 4071 |
|
|
2025
Q2 | $48.7K | Sell |
9,182
-47,523
| -84% | -$256K | ﹤0.01% | 4103 |
|
|
2025
Q1 | $251K | Buy |
56,705
+4,393
| +8% | +$28.4K | ﹤0.01% | 3772 |
|
|
2024
Q4 | $366K | Buy |
52,312
+1,030
| +2% | +$11.3K | ﹤0.01% | 3706 |
|
|
2024
Q3 | $744K | Buy |
51,282
+6,104
| +14% | +$275K | ﹤0.01% | 3528 |
|
|
2024
Q2 | $3.29M | Buy |
45,178
+3,918
| +9% | +$301K | ﹤0.01% | 3100 |
|
|
2024
Q1 | $2.44M | Buy |
41,260
+2,333
| +6% | +$129K | ﹤0.01% | 3215 |
|
|
2023
Q4 | $2.85M | Buy |
38,927
+653
| +2% | +$26.8K | ﹤0.01% | 3187 |
|
|
2023
Q3 | $1.49M | Buy |
38,274
+663
| +2% | +$33.7K | ﹤0.01% | 3430 |
|
|
2023
Q2 | $2.17M | Buy |
37,611
+30,839
| +455% | +$1.87M | ﹤0.01% | 3377 |
|
|
2023
Q1 | $440K | Buy |
6,772
+490
| +8% | +$29.6K | ﹤0.01% | 3782 |
|
|
2022
Q4 | $173K | Hold |
6,282
| – | – | ﹤0.01% | 4163 |
|
|
2022
Q3 | $183K | Sell |
6,282
-2,000
| -24% | -$68.5K | ﹤0.01% | 4190 |
|
|
2022
Q2 | $159K | Sell |
8,282
-14,822
| -64% | -$745K | ﹤0.01% | 4309 |
|
|
2022
Q1 | $1.87M | Buy |
23,104
+462
| +2% | +$38.1K | ﹤0.01% | 3592 |
|
|
2021
Q4 | $2.07M | Sell |
22,642
-123
| -0.5% | -$13.9K | ﹤0.01% | 3625 |
|
|
2021
Q3 | $2.85M | Buy |
22,765
+1,330
| +6% | +$149K | ﹤0.01% | 3512 |
|
|
2021
Q2 | $2.42M | Sell |
21,435
-400
| -2% | -$48.5K | ﹤0.01% | 3513 |
|
|
2021
Q1 | $3.31M | Sell |
21,835
-483
| -2% | -$66.8K | ﹤0.01% | 3228 |
|
|
2020
Q4 | $2.57M | Sell |
22,318
-940
| -4% | -$86.4K | ﹤0.01% | 3265 |
|
|
2020
Q3 | $1.8M | Sell |
23,258
-392
| -2% | -$32.1K | ﹤0.01% | 3240 |
|
|
2020
Q2 | $2.6M | Buy |
23,650
+170
| +0.7% | +$19.7K | ﹤0.01% | 3072 |
|
|
2020
Q1 | $2.57M | Buy |
23,480
+1,028
| +5% | +$135K | ﹤0.01% | 2947 |
|
|
2019
Q4 | $3.57M | Buy |
22,452
+1,609
| +8% | +$237K | ﹤0.01% | 3011 |
|
|
2019
Q3 | $3.08M | Buy |
20,843
+2,710
| +15% | +$302K | ﹤0.01% | 3045 |
|
|
2019
Q2 | $2.11M | Buy |
18,133
+9,645
| +114% | +$905K | ﹤0.01% | 3225 |
|
|
2019
Q1 | $918K | Buy |
8,488
+244
| +3% | +$28.1K | ﹤0.01% | 3353 |
|
|
2018
Q4 | $672K | Buy |
8,244
+3,284
| +66% | +$399K | ﹤0.01% | 3401 |
|
|
2018
Q3 | $808K | Buy |
+4,960
| New | +$847K | ﹤0.01% | 3431 |
|
Other funds holding VRCA
CP
CC
AAA
VCIM
AC
BFM
State Street's VRCA Position: Q2 2026 in Review
State Street held its Verrica Pharmaceuticals (VRCA) position steady in Q2 2026 at 28,916 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #3863.
State Street first reported a position in VRCA in Q3 2018 and has held it in 32 quarters since. The position peaked at $3.57M in Q4 2019. 43 funds tracked by Wall St. Rank hold VRCA as of Q2 2026.
- State Street held 28,916 shares of Verrica Pharmaceuticals worth $177K as of Q2 2026.
- State Street left its Verrica Pharmaceuticals share count unchanged in Q2 2026.
- Verrica Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3863 holding.
- State Street first reported a position in Verrica Pharmaceuticals in Q3 2018 and has held it in 32 quarters since.
- State Street's Verrica Pharmaceuticals position peaked at $3.57M in Q4 2019.
- 43 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.